Background Guidelines for the treatment of chronic obstructive pulmonary disease (COPD)
patients with multiple exacerbations and eosinophilia recommend a long-acting beta 2 …

Background Long-acting β 2 agonists (LABAs) and long-acting muscarinic antagonists
(LAMAs) are the recommended initial maintenance treatment for chronic obstructive …

Background Triple therapy combinations of a long-acting muscarinic antagonist (LAMA), a
long-acting beta 2-agonist (LABA), and an inhaled corticosteroid (ICS) for COPD were …

Background Inhaled corticosteroid/long-acting β 2-agonist combinations (ICS/LABA) have
emerged as first line therapies for chronic obstructive pulmonary disease (COPD) patients …

Background Long-acting β 2-agonists (LABAs) and long-acting muscarinic antagonists
(LAMAs) are recommended as initial maintenance treatments for COPD, with their …

Rationale: Current GOLD strategy document positions both combination regimens of inhaled
corticosteroid plus a long-acting β 2-agonist [ICS/LABA] and LABA plus long-acting …

Introduction Combined inhaled long-acting beta-agonists and corticosteroids (LABA+ ICS)
are costly. They are recommended in severe or very severe chronic obstructive pulmonary …

Introduction: Inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) combinations
are commonly used in the treatment of patients with chronic obstructive pulmonary disease …

Inhaled corticosteroid/long-acting β2-agonist combination therapy is a recommended
treatment option for patients with chronic obstructive pulmonary disease (COPD) and …

Introduction Recently, the generic formulation of FP/SAL FDC has been approved in COPD.
Although FP/SAL FDC has been the first long-acting FDC approved in COPD, no systematic …